These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35262053)

  • 1. The CHRONOS Real-World Evidence of Biologic Treatments in Psoriatic Arthritis in Italy: A
    Colombo D; Frassi M; Mariano GP; Fusaro E; Lomater C; Medico PD; Iannone F; Foti R; Limonta M; Marchesoni A; Raffeiner B; Viapiana O; Di Carlo M; Grembiale RD; Guggino G; Faggioli P; Tirri E; Perricone R; Puttini PCS; Vita S; Conti F; Rizzoli S; Roncari B; Fiocchi M; Orsenigo R; Zagni E
    Womens Health Rep (New Rochelle); 2022; 3(1):162-171. PubMed ID: 35262053
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study.
    Colombo D; Frassi M; Pagano Mariano G; Fusaro E; Lomater C; Del Medico P; Iannone F; Foti R; Limonta M; Marchesoni A; Raffeiner B; Viapiana O; Grassi W; Grembiale RD; Guggino G; Mazzone A; Tirri E; Perricone R; Sarzi Puttini PC; De Vita S; Conti F; Ori A; Simoni L; Fiocchi M; Orsenigo R; Zagni E;
    BMC Rheumatol; 2022 Sep; 6(1):57. PubMed ID: 36089612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CANOVA Study Real-World Evidence of Biologic Treatments in Moderate-Severe Psoriasis in Italy: A Gender Perspective.
    Colombo D; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Zullo A; Ferri F; Fiocchi M; Zagni E
    Womens Health Rep (New Rochelle); 2022; 3(1):450-457. PubMed ID: 35651996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study.
    Zagni E; Frassi M; Mariano GP; Fusaro E; Lomater C; Del Medico P; Iannone F; Foti R; Limonta M; Marchesoni A; Raffeiner B; Viapiana O; Grassi W; Grembiale RD; Guggino G; Mazzone A; Tirri E; Perricone R; Sarzi Puttini PC; De Vita S; Conti F; Zullo A; Simoni L; Fiocchi M; Orsenigo R; Colombo D
    BMC Health Serv Res; 2022 Dec; 22(1):1537. PubMed ID: 36527051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
    McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
    RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
    Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
    Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA.
    Iannone F; Favalli EG; Caporali R; D'Angelo S; Cantatore FP; Sarzi-Puttini P; Foti R; Conti F; Carletto A; Gremese E; Cauli A; Ramonda R; Palermo A; Epis O; Priora M; Bergossi F; Frediani B; Salaffi F; Lopalco G; Cacciapaglia F; Marchesoni A; Biggioggiero M; Bugatti S; Balduzzi S; Carriero A; Corrado A; Bongiovanni S; Benenati A; Miranda F; Fracassi E; Perra D; Ferraccioli G; Lapadula G
    Joint Bone Spine; 2021 Jan; 88(1):105062. PubMed ID: 32755721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of FDA-Approved Medications: Biologics for Psoriatic Arthritis in Patients at an Urban Outpatient Rheumatology Clinic.
    Khanna I; Kozicky O; Fischer H
    ACR Open Rheumatol; 2019 Nov; 1(9):580-584. PubMed ID: 31777842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of acute and chronic viral seropositivity and characteristics of disease in patients with psoriatic arthritis treated with cyclosporine: a post hoc analysis from a sex point of view on the observational study of infectious events in psoriasis complicated by active psoriatic arthritis.
    Colombo D; Chimenti S; Grossi PA; Marchesoni A; Bardazzi F; Ayala F; Simoni L; Vassellatti D; Bellia G
    Clin Cosmet Investig Dermatol; 2016; 9():1-7. PubMed ID: 26730206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis.
    Klavdianou K; Lazarini A; Grivas A; Tseronis D; Tsalapaki C; Rapsomaniki P; Antonatou K; Thomas K; Boumpas D; Katsimbri P; Vassilopoulos D
    Front Med (Lausanne); 2020; 7():288. PubMed ID: 32637422
    [No Abstract]   [Full Text] [Related]  

  • 14. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
    Brahe CH; Ørnbjerg LM; Jacobsson L; Nissen MJ; Kristianslund EK; Mann H; Santos MJ; Reino JG; Nordström D; Rotar Z; Gudbjornsson B; Onen F; Codreanu C; Lindström U; Möller B; Kvien TK; Pavelka K; Barcelos A; Sánchez-Piedra C; Eklund KK; Tomšič M; Love TJ; Can G; Ionescu R; Loft AG; van der Horst-Bruinsma IE; Macfarlane GJ; Iannone F; Hyldstrup LH; Krogh NS; Østergaard M; Hetland ML
    Rheumatology (Oxford); 2020 Jul; 59(7):1640-1650. PubMed ID: 31665497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
    Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
    Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
    Iannone F; Santo L; Bucci R; Semeraro A; Carlino G; Paoletti F; Quarta L; Leucci P; Zuccaro C; Marsico A; Scioscia C; D'Onofrio F; Mazzotta D; Muratore M; Cantatore FP; Lapadula G
    Clin Rheumatol; 2018 Mar; 37(3):667-675. PubMed ID: 29411182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis.
    Wells AF; Curtis JR; Betts KA; Douglas K; Du EX; Ganguli A
    Clin Ther; 2017 Aug; 39(8):1680-1694.e2. PubMed ID: 28734661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study.
    Ramonda R; Lorenzin M; Carriero A; Chimenti MS; Scarpa R; Marchesoni A; Lubrano di Scorpaniello E; Salvarani C; Cauli A; Semeraro A; Santo L; Ortolan A; Doria A; Fracassi E; Virelli G; Masia M; Fanizzi R; Visalli E; Amato G; Carletto A; Foti R;
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33593933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis.
    Nakagawa H; Tanaka Y; Sano S; Kameda H; Taniguchi A; Kashiwagi T; Kawaberi T; Kimura J; Morita A
    Adv Ther; 2019 Mar; 36(3):691-707. PubMed ID: 30661197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.